

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4295637

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASTEX PHARMACEUTICALS, INC.	02/15/2017
RECEIVING PARTY DATA		
Name:	OTSUKA PHARMACEUTICAL CO., LTD.	
Street Address:	2-9 KANDA TSUKASA-MACHI, CHIYODA-KU	
City:	TOKYO	
State/Country:	JAPAN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15200086
CORRESPONDENCE DATA		
Fax Number:	(650)493-6811	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	rgallo@wsgr.com, patentdocket@wsgr.com	
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI	
Address Line 1:	650 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1050	
ATTORNEY DOCKET NUMBER:	12636-369.201	
NAME OF SUBMITTER:	TRISHA AGRAWAL	
SIGNATURE:	/Trisha Agrawal/	
DATE SIGNED:	02/28/2017	
Total Attachments: 4		
source=Astex_12636_369_201_ExecutedAssignment#page1.tif		
source=Astex_12636_369_201_ExecutedAssignment#page2.tif		
source=Astex_12636_369_201_ExecutedAssignment#page3.tif		
source=Astex_12636_369_201_ExecutedAssignment#page4.tif		

ASSIGNMENT AGREEMENT

AGREEMENT by and between:

Sanjeev REDKAR, a citizen of the United States, residing at

2208 Rosemount Lane, San Ramon CA 94582; and

Rajashree JOSHI-HANGAL, a citizen of the United States, residing at

1070 W Lagoon Rd. Pleasanton, CA - 94566

the foregoing parties alternatively and collectively denominated herein as the INVENTORS;
and

Astex Pharmaceuticals, Inc., having offices at 4420 Rosewood Drive, Suite 200,
Pleasanton, CA, 94588,

all of the above parties denominated herein individually and collectively as **ASSIGNORS**; and

Otsuka Pharmaceutical Co., Ltd., a Japanese corporation, with an office at
2-9 Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, Japan,

denominated herein as **ASSIGNEE**;

WITNESSETH:

WHEREAS, the INVENTORS have invented certain new and useful improvements in

LYOPHILIZED PHARMACEUTICAL COMPOSITIONS

for which a Non Provisional Application for Letters Patents in the United States was filed on 1 July 2016 and was accorded U.S. Serial No. 15/200,086 (the "U.S. Non Provisional Application"); and

WHEREAS, **ASSIGNOR Astex Pharmaceuticals, Inc.** holds certain right, title and interest in, to and under said improvements and the said U.S. Non Provisional Application through its employment of INVENTORS **Sanjeev REDKAR** and **Rajashree JOSHI-HANGAL**; and

WHEREAS, **INVENTORS Sanjeev REDKAR** and **Rajashree JOSHI-HANGAL** desire, by this document, to confirm the ownership of their entire right, title and interest in, to and under said improvements and the said U.S. Non Provisional Application by **ASSIGNOR Astex Pharmaceuticals, Inc.**; and

WHEREAS, **ASSIGNEE Otsuka Pharmaceutical Co., Ltd.** is desirous of obtaining the entire right, title and interest in, to and under the said improvements and the said U.S. Non Provisional Application, as held by all **ASSIGNORS** herein; and

WHEREAS all ASSIGNORS are desirous of vesting said entire right, title and interest in, to and under the said improvements and the said U.S. Non Provisional Application to ASSIGNEE.

NOW, THEREFORE, for other good and valuable consideration, the receipt of which is hereby acknowledged,

(i) the said

Sanjeev REDKAR and Rajashree JOSHI-HANGAL

confirm that we have assigned, transferred and set over, and to the extent not already done so, by these presents do hereby assign, transfer and set over, to the said

Astex Pharmaceuticals, Inc.,

its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said improvements, and the said U.S. Non Provisional Application and all divisions, renewals, and continuations thereof and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in any country or countries foreign to the United States, including the right to claim priority under the terms of any appropriate International Convention based upon said application for Letters Patent of the United States, and all Letters Patent which may be granted from said improvements in any country or countries foreign to the United States and extensions, renewals and reissues thereof, and including the right to sue for past infringement; and we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States, whose duty is to issue patents on applications as aforesaid, to issue all Letters Patent for said improvements to the said

Astex Pharmaceuticals, Inc.,

its successors, legal representatives and assigns, in accordance with the terms of this assignment agreement; and

(ii) the said

Astex Pharmaceuticals, Inc.,

confirm that we have assigned, transferred and set over, and to the extent not already done so by these presents do hereby assign, transfer and set over, to the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said improvements, and the said U.S. Non Provisional Application and all divisions, renewals, and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in any country or countries foreign to the United States, including the

right to claim priority under the terms of any appropriate International Convention based upon said application for Letters Patent of the United States, and all Letters Patent which may be granted from said improvements in any country or countries foreign to the United States and extensions, renewals and reissues thereof, and including the right to sue for past infringement; and we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States, whose duty is to issue patents on applications as aforesaid, to issue all Letters Patent for said improvements to the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, in accordance with the terms of this assignment agreement.

AND THE INVENTORS HEREBY further covenant and agree that we will, upon reasonable request of said

Otsuka Pharmaceutical Co., Ltd.,

communicate to the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, any fact known to us respecting said improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisions, continuing and reissue applications, make all rightful oaths and generally do everything reasonable to aid the said

Otsuka Pharmaceutical Co., Ltd.,

its successors, legal representatives and assigns, to obtain and enforce proper protection under patent laws for said improvements in the United States and in any country or countries foreign to the United States.

IN TESTIMONY WHEREOF, the said **Sanjeev REDKAR, Rajashree JOSHI-HANGAL, Astex Pharmaceuticals, Inc., and Otsuka Pharmaceutical Co., Ltd.** have executed this assignment agreement on the date opposite each signature.

This assignment agreement may be executed in counterparts.



Sanjeev REDKAR

Date: 13 February 2017



Rajashree JOSHI-HANGAL

Date: 13 OCT 2016

Astex Pharmaceuticals, Inc.

Date: 2/15/2017




By: Martin Dufford

Title: Astex Pharmaceuticals, Inc
Chief Corporate Officer

Otsuka Pharmaceutical Co., Ltd.

Date: 2/15/2017



By: Nagai Osamu

Title: Director of Intellectual Property,
Otsuka Pharmaceutical Co. Ltd.